Stevanato Group Earnings Call: Growth With Constraints

Stevanato Group Spa ((STVN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Stevanato Group’s latest earnings call struck a cautiously optimistic tone, with management balancing strong Biopharmaceutical & Diagnostic Solutions growth and expanding high‑value offerings against clear pressure points. Investors heard a story of solid demand and margin progress on an adjusted basis, tempered by Engineering weakness, FX and tariff headwinds, and heavy capex weighing on free cash flow.

Revenue Growth Supported by Resilient Demand

Stevanato delivered 10% constant‑currency revenue growth, or 7% reported, lifting Q1 sales to EUR 273.6 million versus the prior year. Management framed this as evidence of resilient end‑market demand despite currency pressure and uneven performance across segments.

BDS Segment Anchors Performance

The Biopharmaceutical & Diagnostic Solutions segment was the clear growth engine, with revenue up 16% at constant currency and 13% reported to EUR 249.0 million. Strength in pre‑fillable syringes, cartridges and vials underpinned this performance, more than offsetting softness elsewhere.

Syringes, Biologics and GLP‑1s Drive Momentum

Syringe revenue surged more than 20% year on year, while biologics revenue climbed 15%, making it the fastest‑growing end market. GLP‑1 products represented roughly 21%–22% of total company revenue, underscoring Stevanato’s leverage to this structurally expanding therapy category.

High‑Value Solutions Increase Share of the Mix

Revenue from high‑value solutions rose 17% to EUR 128.6 million, now accounting for 47% of company sales and about 52% of BDS revenue. This richer mix is central to the margin story and signals continued strategic pivot toward more sophisticated, higher‑margin offerings.

Adjusted Profitability and Margins Trend Higher

On an adjusted basis, EBITDA grew 14% to EUR 65.5 million, expanding the adjusted EBITDA margin by 150 basis points to 23.9%. Adjusted net profit advanced 5% to EUR 29.6 million, with adjusted diluted EPS up 10% to EUR 0.11, reflecting operating leverage from the high‑value mix.

Gross and Operating Margins Edge Up

Companywide gross margin improved by 30 basis points to 27.5%, while operating margin increased 70 basis points to 14.2% in the quarter. Management highlighted these gains as evidence that productivity measures and mix upgrades are beginning to offset cost pressures.

Capacity Expansion and Operational Execution

Stevanato reported tangible progress on its capacity build‑out, including converting an underutilized ready‑to‑use vial line into a cartridge line that should enter commercial production in the coming weeks. Ramps at Latina and Fishers are on track, with device assembly and automation expected to support commercial volumes between late 2026 and early 2027.

Cash Generation and Heavy Growth Investment

Operating cash flow reached EUR 75.5 million in Q1, but substantial capital expenditures of EUR 67.6 million left free cash flow at just EUR 5.5 million. More than 90% of capex went to the Fishers and Latina growth projects, leaving the company with EUR 111.7 million of cash while it maintains its full‑year outlook.

Engineering Margins Show Early Recovery Signs

Within the Engineering segment, profitability metrics showed improvement despite a challenging top line, as gross margin rose 460 basis points to 15.3%. Operating margin increased 190 basis points to 6.6%, reflecting benefits from optimization and right‑sizing initiatives underway.

Engineering Revenue Under Significant Pressure

Engineering revenue fell sharply, down 31% year over year to EUR 24.6 million, as a low starting backlog and slower new order intake weighed on sales. Management acknowledged that elongated customer decision cycles create timing risk for a revenue rebound in this business.

BDS Margins Hit by Depreciation and FX

In contrast to the companywide margin gains, BDS gross margin contracted by 300 basis points to 28.3% in Q1. The segment was burdened by roughly EUR 4 million of ramp‑related depreciation, currency effects, temporary tariffs and the absence of a high‑margin pilot project that benefited the prior year.

FX, Depreciation and Tariffs Create Headwinds

Stevanato flagged currency as a meaningful drag, estimating an approximate EUR 18 million full‑year revenue headwind, while higher depreciation intensified near‑term margin pressure. Tariff‑related costs of about EUR 1.7 million also weighed on Q1 profitability, though some of these are expected to be recoverable later.

Tax Rate and Leverage Weigh on Bottom Line

The effective tax rate climbed to 28.6% from 24.5%, following the end of a prior tax incentive, reducing net income retention despite operational gains. Net debt stood at EUR 337.7 million, and with capex absorbing much of the quarter’s cash generation, leverage and modest free cash flow remain watch points.

Slower Sales Cycles and Cartridge Constraints

Management noted longer sales and decision cycles in Engineering, and while commercial capacity is being strengthened, the timing of order conversion remains uncertain. At the same time, demand for cartridges is outpacing expectations, creating capacity constraints that the company is addressing through line conversions and new capacity extending into 2027.

Guidance and Outlook Emphasize H2 Strength

Stevanato reaffirmed its 2026 guidance, calling for revenue of EUR 1.260–1.290 billion, adjusted EBITDA of EUR 331.8–346.9 million and adjusted EPS of EUR 0.59–0.63. Management expects high‑value solutions to reach about 47%–48% of revenue, GLP‑1 volumes to grow in the mid‑teens, BDS margins to at least match 2025, and a back‑half‑weighted year with stronger H2 and softer Engineering.

Stevanato’s earnings call painted a picture of a company leaning into secular growth in biologics and GLP‑1 therapies while investing heavily in future capacity. For investors, the key takeaway is that near‑term noise from FX, tariffs, capex and Engineering volatility is being managed against a backdrop of structurally rising demand and a richer, higher‑value product mix.